Prostaglandins, including PGD 2 and PGE 2 , are produced during allergic reactions. Although PGD 2 is an important mediator of allergic responses, aspirin-like drugs that inhibit prostaglandin synthesis are generally ineffective in allergic disorders, suggesting that another prostaglandin-mediated pathway prevents the development of allergic reactions. Here we show that such a pathway may be mediated by PGE 2 acting at the prostaglandin E receptor EP3. Mice lacking EP3 developed allergic inflammation that was much more pronounced than that in wild-type mice or mice deficient in other prostaglandin E receptor subtypes. Conversely, an EP3-selective agonist suppressed the inflammation. This suppression was effective when the agonist was administered 3 h after antigen challenge and was associated with inhibition of allergy-related gene expression. Thus, the PGE 2 -EP3 pathway is an important negative modulator of allergic reactions.
Allergy, especially type I allergy such as bronchial asthma and allergic rhinoconjunctivitis, is a principal health problem, and the prevalence of allergy has increased during the past two decades 1 . Affected people have a high titer of immunoglobulin E (IgE) antibodies specific for allergens such as those associated with house dust mites and plant pollen 2 . Exposure of such people to these allergens induces the activation of mast cells through crosslinking of IgE receptors on the cell surface mediated by antigen-antibody binding. Activated mast cells release allergic mediators such as histamine, cysteinyl leukotrienes and various cytokines. These substances not only mediate acute allergic responses but also induce the late phase of inflammation by stimulating local synthesis of various chemokines such as CCL11 (eotaxin) and CCL17 (TARC), which recruit T helper type 2 lymphocytes and eosinophils [3] [4] [5] . Repeated exposure to allergens enhances inflammation characterized by infiltration of these cells and can cause tissue remodeling. However, how this course of responses is regulated and why it becomes exaggerated in some populations remains unknown.
Prostaglandins, including PGD 2 and PGE 2 , are produced in substantial amounts during allergen exposure and disease development [4] [5] [6] [7] . Prostaglandins act at specific cell surface receptors to elicit their own actions. Whereas PGD 2 acts at the prostaglandin D receptor, PGE 2 acts at four subtypes of prostaglandin E receptor, EP1-EP4 (ref. 8) , which are encoded by Ptger1-Ptger4. Studies examining the function of PGD 2 in allergic asthma using mice deficient in the prostaglandin D receptor found that PGD 2 mediates this disease 9 . This view has been supported by a genetic study in humans identifying the gene encoding PGD 2 as an 'asthma susceptibility gene' 10 .
If PGD 2 were the only prostaglandin important in allergy, aspirin-like nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit prostaglandin synthesis would be expected to suppress allergic reactions. However, these drugs are generally ineffective in the treatment of allergic disorders. In contrast, they induce life-threatening attacks in about 10% of adults with asthma 11 and aggravate nasal polyposis of allergic rhinitis 12 . Patients who develop aspirin-induced asthma also manifest other symptoms of immediate hypersensitivity such as rhinorrhea, conjunctival irritation and flushing of the head and neck. These observations suggest the existence of a prostaglandindependent process that suppresses type I allergic reactions in general. Here, we have examined mice deficient in each prostaglandin E receptor subtype individually and have used an EP3-selective agonist to identify this protective prostaglandin pathway. We show that the PGE 2 -EP3 pathway is an important negative modulator of allergic reactions.
RESULTS
Enhanced allergic responses in Ptger3 À/À mice Because studies have described attenuation by PGE 2 in various asthmatic responses 13, 14 , we subjected mice deficient in each individual prostaglandin E receptor subtype [15] [16] [17] to the ovalbumin (OVA)-induced asthma model and examined their responses. We backcrossed Ptger1 À/À , Ptger2 À/À and Ptger3 À/À mice for at least eight generations onto the C57BL/6 background and used wild-type C57BL/6 mice as controls. Ptger4 À/À mice do not survive on the C57BL/6 background because of the development of patent ductus arteriosus 17, 18 ; we therefore intercrossed survivors of F 2 progeny and studied the resultant Ptger4 +/+ and Ptger4 À/À survivors on the mixed genetic background of 129/Ola Â C57BL/6.
We used OVA-induced allergic asthma as a model of type I allergy 9 . We sensitized the mice by intraperitoneal injection of OVA on days 0 and 12 and then exposed them to aerosolized OVA on days 22, 26 and 30. We then killed the mice 24 h after the last antigen challenge and collected bronchoalveolar lavage fluid (BALF). Antigen inhalation induced an increase in the number of inflammatory cells in BALF in all strains of mice examined. However, the BALF of Ptger3 À/À mice contained significantly more cells than that of wild-type, Ptger1 À/À or Ptger2 À/À mice (Fig. 1a) . The number of cells in the BALF of Ptger4 À/À mice was greater than that in wild-type C57BL/6 mice but did not differ significantly from that of Ptger4 +/+ mice (Fig. 1a) .
We next examined whether the exaggerated allergic inflammation in Ptger3 À/À mice could be attributed to a higher serum concentration of IgE. On day 12, after the second OVA injection, the serum concentrations of total IgE were 1,469 7 676 pg/ml and 1,802 7 325 pg/ml and those of OVA-specific IgE were 149 7 85 U/ml and 112 7 40 U/ml in wild-type and Ptger3 À/À mice, respectively (n ¼ 5 of each). On day 31, the concentration of total IgE in Ptger3 À/À mice was significantly higher than that of wild-type mice (1,706 7 542 pg/ml versus 592 7 286 pg/ml; n ¼ 5; P o 0.05). However, the concentration of OVA-specific IgE did not differ significantly between the two groups (41 7 25 U/ml versus 72 7 28 U/ml for wild-type and Ptger3 À/À mice, respectively; n ¼ 5; P ¼ 0.28). Ptger3 À/À mice thus demonstrated exaggerated allergic inflammation, as assessed by cellular infiltration, despite serum concentrations of antigen-specific IgE similar to those of wild-type mice, indicating that EP3 deficiency enhanced the allergic response at a step or steps subsequent to IgE synthesis. We confirmed this conclusion using a passive cutaneous anaphylaxis (PCA) test, which monitors the allergic response to fixed amounts of exogenous dinitrophenyl and dinitrophenyl-specific IgE. The exudation reaction of Ptger3 À/À mice from the PCA test was significantly greater than that of wild-type mice in this assay (Fig. 1b) .
Allergic inflammation is characterized by infiltration of eosinophilic leukocytes and T helper type 2 lymphocytes [3] [4] [5] . Eosinophils constituted the main fraction of the inflammatory cells in BALF of both Ptger3 À/À and wild-type mice subjected to OVA sensitization and challenge. However, their number was significantly higher in Ptger3 À/À mice than in wild-type mice (Fig. 2a) . Ptger3 À/À mice also had more lymphocytes and neutrophils in BALF, whereas the numbers of macrophages were similar for the two groups. Concentrations of the T helper type 2 cytokines interleukins 4, 5 and 13 in BALF were increased by antigen challenge in both groups (Fig. 2b) . However, Ptger3 À/À mice had much higher concentrations than did wildtype mice, whereas the concentration of the T helper type 1 cytokine interferon-g in BALF did not differ significantly between the two genotypes (P ¼ 0.103, wild-type versus Ptger3 À/À ). Histological examination showed that lymphocytes, eosinophils and other leukocytes accumulated in the perivascular and peribronchial regions of the lungs of both groups of mice, but quantitative analysis showed that the cell infiltration was more extensive in Ptger3 À/À mice (Fig. 2c) . Thus, the allergic inflammation in Ptger3 À/À mice was much more pronounced than that in wild-type mice.
Antiallergic effects of an EP3 agonist in vivo Our results suggested that PGE 2 acts at the EP3 receptor during elicitation of allergy and downregulates allergic reactions. To verify this conclusion, we examined the effects of an EP3-selective agonist, ONO-AE-248 (AE-248) 19 , and of a nonselective stable PGE 2 analog, 16,16-dimethyl-PGE 2 (dm-PGE 2 ), on OVA-induced asthma in wildtype mice. We administered these compounds subcutaneously to OVA-sensitized mice beginning on day 21. As a positive control, we administered the glucocorticoid prednisolone, the drug used most prevalently for clinical asthma therapy, once a day from day 21 to day 30. We collected BALF 24 h after the last OVA challenge and assessed the effects of these compounds on cell infiltration. The EP3 agonist AE-248 significantly inhibited the antigen-induced infiltration of inflammatory cells (Fig. 3a) . This inhibitory effect was absent from Ptger3 À/À mice, confirming that it was mediated by EP3. In contrast, dm-PGE 2 did not significantly affect cell infiltration compared with that resulting from vehicle treatment at this dose (P ¼ 0.219). The inhibitory effect of AE-248 at a dose of 10 mg/kg was similar to that obtained with prednisolone at a dose of 5 mg/kg for reducing asthmatic symptoms. Cell population analysis showed that the EP3 agonist significantly suppressed infiltration of eosinophils, lymphocytes and neutrophils to an extent similar to that noted with prednisolone; although prednisolone also inhibited macrophage infiltration, AE-248 did not (Fig. 3b) . The suppressive effect of AE-248 on eosinophil infiltration was apparent at a dose of 0.1 mg/kg and was significant at doses of 1 mg/kg and 10 mg/kg (Fig. 3c) .
We next attempted to optimize the regimen of AE-248 treatment with regard to suppression of the allergic reaction. We limited administration of the compound to the days of antigen challenge only (days 22, 26 and 30) , either twice at 30 min before and 3 h after OVA challenge or once at either 30 min before or 3 or 12 h after the challenge. We compared the antiallergic effects at 24 h after the last antigen inhalation. We noted suppression of inflammatory cell infiltration similar to that obtained in the original treatment protocol in mice treated with the EP3 agonist either twice at 30 min before and 3 h after or once 3 h after antigen challenge on days 22, 26 and 30 only (Fig. 3d) . Treatment with the compound once at 30 min before antigen challenge tended to reduce the number of inflammatory cells (P ¼ 0.165, 30 min before versus vehicle), but treatment 12 h after challenge had no effect. In addition to the anti-inflammatory effect, administration of the EP3 agonist 3 h after OVA challenge tended to reduce the number of periodic acid Schiff (PAS)-positive cells in the lungs and airway hypersensitivity (Fig. 3e,f) . These results indicate that administration of the EP3 agonist suppresses allergic inflammation.
EP3 agonist suppresses allergen-induced mediator release
Our results showed that PGE 2 acts at EP3 during allergy to suppress allergic inflammation. To provide mechanistic insight into this EP3-mediated action, we examined the effects of the EP3 agonist on antigen-induced allergic mediator release in vitro. We isolated cells from the lungs from OVA-sensitized wild-type mice on day 19 after sensitization, which we then challenged by adding OVA to the cell cultures, and then measured the release of histamine and cysteinyl leukotrienes. The OVA challenge induced a significant increase in histamine release from the sensitized lung tissue cells (Fig. 4a) . This effect of OVA was augmented by pretreatment of the tissue with indomethacin, and this effect of indomethacin was blocked by PGE 2 or AE-248 but not by agonists selective for EP1, EP2 or EP4.
To confirm the function of EP3 in this phenomenon, we repeated the experiments with lung tissue from OVA-sensitized Ptger3 À/À mice. Stimulation of the tissue with OVA alone induced the release of a substantially more histamine than that found in wild-type mice. Moreover, this response was not affected by indomethacin, PGE 2 or AE-248 (Fig. 4b) . We obtained essentially identical results by analysis of OVA-induced cysteinyl leukotriene release from lung tissue of wild-type and Ptger3 À/À mice (Fig. 4c,d ). Given that most of the histamine and cysteinyl leukotrienes released in response to antigen challenge is derived from mast cells, these results suggest that PGE 2 acts at EP3 in mast cells to suppress mediator release. The augmentation of mediator release by indomethacin further indicates that such inhibition occurs in a feedback way through endogenous PGE 2 production.
EP3 agonist inhibits allergy-related gene expression
Although our results showed that the EP3 agonist inhibits mediator release, this effect alone cannot explain the action of the compound in vivo, given that the agonist suppressed allergic inflammation even when administered 3 h after antigen inhalation (Fig. 3d) . To further address the mechanism of action of the EP3 agonist, we did DNA microarray analysis. We subjected OVA-sensitized wild-type mice (n ¼ 3 per group) to inhalation of either OVA or saline on days 22, 26 and 30 and injected the OVA-challenged mice with either vehicle or the EP3 agonist 3 h after each antigen challenge; we injected the saline-challenged control mice with vehicle instead of the EP3 agonist. We isolated lung tissue from all mice 24 h after the last inhalation and subjected it to microarray analysis with the MG-U74Av2 gene chip that includes probes for 12,426 mouse genes.
We then compared expression of each gene in each of the three control mice with that in each of the three vehicle-treated, OVAchallenged mice using Affymetrix GeneChip Expression Analysis software. We considered a change in the expression of a gene relevant if it differed in more than six of the nine pairs. The expression of 279 of the 12,426 genes was increased considerably and that of 86 genes was decreased considerably in the lungs of the OVA-challenged mice compared with that in the lungs of control mice (Fig. 5a) . We then compared gene expression in the EP3 agonist-treated, OVAchallenged mice with that in the vehicle-treated, OVA-challenged mice in a similar way. Of the 279 genes that showed an antigen-induced increase in expression, 195 genes showed a decrease in expression in response to the EP3 agonist in more than six of the nine comparison pairs. The expression of the remaining 84 genes was also decreased by the agonist but in fewer than six of the nine pairs. Similarly, of the 86 genes that showed an antigen-induced decrease in expression, 38 genes showed an increase in expression in response to the EP3 agonist in more than six of the nine pairs ( Supplementary  Table 1 online) .
Among the genes upregulated by antigen challenge were those for immunoglobulins (68 of 279) and for receptors or markers of lymphocytes and other immune cells (18 of 279). The genes for chemokines or chemokine receptors accounted for 19 of these 279 genes. The upregulation of the first two groups of genes may represent recruitment of lymphocytes and other inflammatory cells, and the induction of the last group of chemokine and chemokine receptor genes may be responsible for such recruitment. The last group included genes encoding CCL17 (TARC), CCL11 (eotaxin) and CCL7 (MCP-3), the expression of each of which was upregulated significantly after antigen challenge and whose induction was completely inhibited by the EP3 agonist. We confirmed these changes by RT-PCR analysis (Fig. 5b) . Each of these chemokines has been linked to allergic asthma and allergic rhinoconjunctivitis 4, 5 . These results suggest that the EP3 agonist suppresses allergic inflammation through inhibition of the induction of chemokine genes.
We also detected induction by antigen exposure and suppression by the EP3 agonist of the expression of other genes involved in tissue metaplasia, remodeling and resolution [20] [21] [22] [23] [24] , including those encoding Clca3 (also called Gob-5), Muc5ac, MMP-12, ADAM-8 and Alox15 (Supplementary Table 1 online) . Muc5ac encodes a core protein of large mucin, and Gob-5 is involved in mucus secretion in the epithelium 20 . Although the decrease in the number of PAS-positive cells by EP3 agonist was limited (Fig. 3e) , suppression of induction of the genes encoding Gob-5 and Muc5ac indicates that the EP3 agonist treatment substantially attenuates goblet cell formation. In contrast, although transcripts of the genes encoding enzymes that contribute to PGE 2 biosynthesis, including cyclooxygenases 1 and 2 and microsomal prostaglandin E synthases 1 and 2, were present in normal lung tissue, their abundance was not substantially affected by OVA challenge with or without treatment with the EP3 agonist. Among the prostaglandin E receptor subtypes, expression of only the gene encoding EP4 was increased substantially by OVA challenge in a way that was sensitive to the EP3 agonist. These results indicate that EP3 agonist administered 3 h after the challenge inhibits allergen-induced gene expression changes. 
Localization of EP3 in the lungs
We next examined the localization of EP3 in the lungs. EP3 mRNA was detected in the lungs of wild-type mice by RT-PCR analysis, and its abundance was not affected by OVA challenge (Fig. 6a) . Consistently, when we enriched BALF from challenged mice for CD11b + cells, including macrophages, neutrophils and eosinophils, or CD4 + T cells, and analyzed the cells by RT-PCR, we detected little expression of EP3 mRNA in these cells (Fig. 6a) . Given that antibodies to mouse EP3 suitable for immunohistochemistry were not available, we used Ptger3 À/À mice in which the b-galactosidase gene was 'knocked-in' at the EP3 gene locus to examine EP3 localization. Staining for b-galactosidase activity showed positive signals in airway epithelial cells of the engineered mice but not in those of wild-type mice (Fig. 6b) . In contrast, consistent with the PCR analysis reported above, b-galactosidase signals were barely detectable in the cells infiltrating in the lung parenchyma (Fig. 6b) . To determine the possible relationship between EP3 localization and its regulation of gene expression, we examined by immunohistochemistry the site of allergen-induced chemokine production. CCL17 immunoreactivity was induced by OVA challenge in the airway epithelial cells of sensitized wild-type mice, and this effect was inhibited by treatment with the EP3 agonist (Fig. 6c) . We obtained essentially identical results for CCL11 expression (data not shown). These data suggested that EP3 is constitutively present on the surface of airway epithelial cells and that EP3 signaling in these cells inhibits the allergen-induced expression of chemokine genes.
DISCUSSION
Allergic inflammation is initiated by mast cell activation as acute vascular responses and develops into inflammation characterized by infiltration of T helper type 2 lymphocytes and eosinophils, leading to tissue metaplasia and remodeling. This process of progression is similarly seen in bronchial asthma and allergic rhinitis and conjunctivitis [3] [4] [5] . Using OVA-induced allergic asthma as a model, we have shown here that PGE 2 -EP3 signaling negatively regulates this progression of allergic inflammation. This is consistent with published findings that inhaled PGE 2 suppresses allergen-induced inflammation in human asthmatic patients 13, 25 . Given the similarity of allergic rhinoconjunctivitis to asthma, it is very likely that EP3 signaling also modulates the process of allergic rhinitis and allergic conjunctivitis. The PGD 2 -prostaglandin D receptor pathway mediates allergic responses 9 . That pathway and the PGE 2 -EP3 pathway thus exert opposing actions in allergic inflammation. Furthermore, mice deficient Figure 5 Effects of OVA challenge and the EP3 agonist on gene expression in the lungs. (a) Microarray analysis. Wild-type mice were sensitized with OVA and were treated with either AE-248 or vehicle 3 h after each challenge with OVA or saline. Lung tissue was isolated 24 h after the last challenge, and polyadenylated RNA was assessed by microarray analysis. Top bar, proportion of genes whose expression was increased (red) or decreased (blue) in the vehicle-treated, OVA-challenged mice compared with that in the vehicle-treated, saline-challenged mice. Bottom bars, effects of the EP3 agonist on the expression of genes affected by OVA challenge. Blue or turquoise, number of genes that decreased in more or less, respectively, than six of nine pairs by EP3 agonist treatment; red or orange, number of genes that increased in more or less, respectively, than six of nine pairs by EP3 agonist treatment. The aggravation of allergic diseases by aspirin-like NSAIDs is known as aspirin intolerance and occurs in patients with asthma and/or nasal polyposis 11, 12 . Despite a high incidence of aspirin intolerance in these patients, the underlying mechanism has remained controversial. A prevailing hypothesis has been that NSAIDs shunt the substrate arachidonic acid from the cyclooxygenase pathway to the alternative lipoxygenase pathway, resulting in enhanced production of proinflammatory and proasthmatic leukotrienes. Our finding that allergic reactions are enhanced in Ptger3 À/À mice without inhibition of cyclooxygenase challenges this hypothesis and suggests that the PGE 2 -EP3-mediated suppression of allergic inflammation is a long-sought target mechanism of aspirin intolerance. Although it remains unclear why patients with aspirin-induced asthma are more vulnerable to inhibition of prostaglandin synthesis, it is likely that these people depend more on protection by the PGE 2 -EP3 pathway than do patients without aspirin-induced asthma.
We have shown that endogenous PGE 2 acting at EP3 has an important feedback function in allergic inflammation and that administration of an EP3-selective agonist substantially suppresses elicitation of allergic inflammatory reactions. Notably, the EP3 agonist was most effective in suppressing allergic inflammation when administered 3 h after antigen challenge. Allergic inflammation consists of two phases: the early-phase reaction, which develops and subsides within 60 min, and the late phase reaction, which starts at 3-6 h, peaks at 6-8 h and subsides 24 h after the antigen challenge. Local synthesis of chemokines and cytokines is crucial for the latephase reaction, and the main site of their synthesis is the epithelium [3] [4] [5] . Notably, EP3 is expressed in airway epithelial cells, where the chemokines CCL11 and CCL17 are also expressed, and administration of the EP3 agonist 3 h after the challenge can inhibit the allergen-induced synthesis of these chemokines. A variety of mediators released from activated mast cells can induce expression of the genes encoding chemokines in the epithelium 4, 5, [30] [31] [32] , and gene expression is detectable 3 h after antigen inhalation 33 . In our preliminary study, we found that the EP3 agonist administered 2 or 3 h after the antigen challenge was most effective, whereas agonist administered 1 or 4 h after the challenge was less effective in suppressing allergic inflammation. The time when treatment with the EP3 agonist is most effective thus coincides with the time of chemokine gene expression. These observations collectively suggest that PGE 2 acts at EP3 on airway epithelial cells and regulates the extent of the late-phase response by attenuating the expression of these chemokine genes. Notably, the prostaglandin D receptor is also expressed in airway epithelial cells, where it acts to enhance allergic inflammation 9 .
Ptger3 À/À mice demonstrate not only exaggerated asthmatic reactions but also enhancement of the PCA reaction, which is caused directly by allergic mediators released from mast cells. Consistent with that observation, we found that the EP3 agonist significantly suppressed the release of histamine and cysteinyl leukotrienes from antigen-sensitized lung tissue. The effects of PGE 2 on the release of mediators from mast cells have remained unclear. Mast cells derived from the bone marrow of mice deficient in EP3 have demonstrated the importance of PGE 2 -EP3 signaling in potentiating antigen-stimulated degranulation 34 . We have detected the EP3 expression in bone marrow-derived mast cells from wild-type mice and found that administration of the EP3 agonist indeed augmented the antigeninduced histamine release (data not shown). In addition, PGE 2 and prostaglandin E analogs were shown to enhance mediator release by an EP1-and/or EP3-dependent mechanism in the MC-9 mast cell line 35 . In contrast, another study showed that the EP2 and EP3 agonist misoprostol inhibited mediator release from rat peritoneal mast cells triggered by antibody to IgE 36 . Given the existence of several subclasses of mast cells that differ in their origin and functions 37 , these different responses to PGE 2 might reflect the differences in cell subclass. Bone marrow-derived mast cells are considered the presumptive in vitro counterpart of in vivo-differentiated mucosal mast cells and are different from mast cells working in allergic reactions in the lung 38 . Our findings suggest that a subclass of mast cells sensitive to EP3 stimulation has a chief function in OVA-induced allergic responses. Alternatively, an EP3-dependent indirect mechanism may operate to suppress mast cell activation in sensitized lungs in vivo.
The EP3 agonist is as potent as the glucocorticoid prednisolone in suppressing allergic inflammation and is able to exert this inhibitory effect at doses in the mg/kg range. Signaling by EP3 is mediated mainly by coupling to the inhibitory G protein G i and results in inhibition of the generation of cyclic AMP. This signaling is elicited at PGE 2 or EP3 agonist concentrations as low as 10 pM (ref. 39) . The antiallergic effect of low doses of the EP3 agonist in the present study might therefore be mediated by this signaling pathway. In addition inhibiting cyclic AMP production, PGE 2 acting at EP3 induces an increase in the intracellular free calcium concentration at doses of 10 nM to 1 mM, an effect mediating such EP3 actions as uterine contraction. Given these facts and also given that the proinflammatory action of PGE 2 is exerted by the EP2 and/or EP4 receptor, the EP3 agonist can circumvent the proinflammatory effects of PGE 2 by its selectivity and also its own adverse effects by administration of a low dose. Its unique property of being effective when administered after antigen challenge, that is, after appearance of early signs of allergy, may make an EP3 agonist a candidate for a new type of antiallergy drug.
METHODS
Animals and compounds. Ptger1 À/À , Ptger2 À/À , Ptger3 À/À and Ptger4 À/À mice were generated as described [15] [16] [17] . Mice were maintained on a 12-hour-12-hour light-dark cycle in specific pathogen-free conditions. All experimental procedures were approved by the Committee on Animal Research of Kyoto University Faculty of Medicine (Kyoto, Japan). The agonists ONO-DI-004, ONO-AE1-259, ONO-AE-248 and ONO-AE1-329 were supplied by ONO Pharmaceutical; the ligand-binding specificities of these compounds for each prostaglandin E receptor subtype have been described 16 . We assessed the pharmacokinetic properties of AE-248 by monitoring the biological response to this compound administered intravenously; injection of rats with a bolus of AE-248 at a dose of 10 mg/kg resulted an increase in blood pressure of in 10 mmHg that persisted for 10 min (data not shown).
Analysis of asthmatic responses. Mice were immunized with OVA and were challenged by OVA inhalation as described 9 . BALF was collected at 8 and 24 h for cytokine measurement and cell analysis, respectively. The concentration of cytokines was measured using enzyme-linked immunosorbent assay (ELISA) kits (Endogen). The number of white blood cells was determined with a hemocytometer, and differential leukocyte counts were made using a smear stained with Diff-Quik solution (International Reagents). The serum concentrations of total and OVA-specific IgE were measured by sandwich ELISA as described 40 .
For examination of the effects of AE-248, dm-PGE 2 (Sigma) and prednisolone (Sigma) on allergic inflammation in the lung, AE-248 (0.1-10 mg/kg) and dm-PGE 2 (10 mg/kg) were administered subcutaneously to OVA-sensitized mice twice a day beginning on day 21, the day before the first OVA challenge; they were also administered in an additional dose 3 h after antigen challenge on days 22, 26 and 30. Prednisolone (5 mg/kg, subcutaneously) was administered once a day from day 21 to day 30. For time course study, administration of the AE-248 was limited to the days of antigen challenge only (days 22, 26 and 30) and the following four treatment protocols were used: twice at 30 min before and 3 h after OVA challenge; once at 30 min before challenge; once at 3 h after the challenge; and once at 12 h after the challenge. BALF was collected 24 h after the last challenge and the accumulation of inflammatory cells was assessed.
For measurement of airway resistance, mice treated with the EP3 agonist or vehicle (saline) were anesthetized 24 h after the last antigen challenge and were ventilated at a tidal volume of 8 ml and a frequency of 2.5 Hz with a Flexivent SAV system (Scientific Respiratory Equipment) as described 41 . Each mouse was challenged by inhalation for 30 s of increasing doses of methacholine (1-100 mg/ml), with the doses administered at intervals of 5 min. Airway resistance was monitored with a heated pneumotachograph, and the peak value induced by each challenge was recorded using an oscillation technique.
Histological analysis. At 24 h after the last antigen challenge, lungs were distended by injection through the trachea of 10% formalin in 0.1 M sodium phosphate, pH 7.4, and then were excised. After immersion in fresh fixative for 24 h, the tissue was embedded in paraffin, sliced into sections 3 mm in thickness and stained with hematoxylin and eosin or with PAS solution. Quantitative analysis was done on microscopic images of three Â100 magnification fields per slide and three slides per mouse for each stain with the use of ImagePro Plus software (Media Cybernetics). Perivascular inflammatory cell infiltration was quantified as the total area of inflammatory cell accumulation relative to the perimeter of the blood vessel. For quantification of mucus-producing cells, the ratio of the PAS-positive area to the total area of the bronchial epithelium was determined. Slides were analyzed by investigators 'blinded' to sample identity and were presented in a random order for each examination.
PCA test. PCA was induced as described 42 . Mice were injected intradermally on the back with 20 ml of antibody to dinitrophenyl IgE (0.3 mg/ml). After 24 h, 0.25 mg of dinitrophenyl-conjugated bovine serum albumin and 1.25 mg of Evans blue in 0.25 ml of saline were injected intravenously to elicit PCA. Vascular permeability was evaluated by measurement of the amount of dye extravasated during the 30 min immediately after antigen challenge. Control mice were injected with the antigen and Evans blue without prior injection with IgE.
Histamine and cysteinyl leukotriene release in vitro. OVA-sensitized mice were killed by exsanguination on day 19 and the lungs were immediately removed and placed in Tyrode's solution. After removal of bronchial tissue and blood vessels, the lungs were chopped into fragments 0.5 mm 3 in size, and the fragments were washed and blotted dry. The tissue fragments (100 mg, wet weight) were suspended in Tyrode's solution at a final volume of 2 ml, were shaken for 10 min at 37 1C in the absence or presence of indomethacin (10 mM), PGE 2 (10 mM) or prostaglandin E receptor agonist (10 mM for EP1, EP2 and EP3 agonists; 1 mM for the EP4 agonist), and then were challenged for 15 min with OVA (10 mg/ml). The tissue and medium were separated by filtration and histamine was extracted from the tissue and the medium and assayed as described 43 . Histamine release is expressed as a percentage of total tissue histamine. Cysteinyl leukotrienes were extracted from the incubation medium with the use of a Sep-Pak C 18 cartridge 44 and were assayed with an ELISA kit for LTC 4 , LTD 4 and LTE 4 (Amersham Pharmacia Biotech).
DNA microarray analysis. At 3 h after each antigen challenge, OVA-challenged mice were injected with either vehicle or AE-248; saline-challenged control mice were injected with vehicle instead of the EP3 agonist. Lung tissue was isolated from all mice 24 h after the last inhalation. Polyadenylated RNA was prepared from lung tissue as described 8 and was subjected to microarray analysis with the MG-U74Av2 gene chip (Affymetrix). Expression of each gene in each of the three control mice was then compared with that in each of the three vehicle-treated, OVA-challenged mice using Affymetrix GeneChip Expression Analysis software (Suite, version 4.0, 3 Â 3 ¼ 9 comparison pairs). A change in the expression of a gene was considered relevant if it differed in more than six of the nine pairs. Comparison of gene expression in the EP3 agonisttreated, OVA-challenged mice with that in the vehicle-treated, OVA-challenged mice was done in a similar way.
RT-PCR. A GeneAmp PCR system 9700 (Perkin Elmer Applied Biosystems) was used for PCR. Primers (sense and antisense, respectively) were 5¢-ATCCTCGTG TACCTGTCACAGCGACGCTGG-3¢ and 5¢-TGCTCAACCGACATCTGATT GAAGATCATT-3¢ for Ptger3 (EP3); 5¢-CAGGAAGTTGGTGAGCTGGTATA-3¢ and 5¢-TTGTGTTCGCCTGTAGTGCATA-3¢ for Ccl17 (TARC); 5¢-AGAGCTC CACAGCGCTTCTATT-3¢ and 5¢-GGTGCATCTGTTGTTGGTGATT-3¢ for Ccl11 (eotaxin); 5¢-CACAACACTAAGGTGGCCTACCTCCAAG-3¢ and 5¢-AC TTGGAGTGAGGTGTTGAAGTGGTCCCT-3¢ for Clca3 (Gob-5); and 5¢-TGA AGGTCGGTGTGAACGGATTTGGC-3¢ and 5¢-CATGTAGGCCATGAGGTCCA CCAC-3¢ for Gapd (glyceraldehyde-3-phosphodehydrogenase).
Cell preparation. AutoMACS (Miltenyi Biotec) was used for preparation of the subpopulations of inflammatory cells in BALF. BALF was recovered 24 h after last challenge from OVA-challenged mice. Samples were enriched for CD11b + and CD4 + cells by auto-MACS with antibody to CD11b or to CD4 MicroBeads, respectively (Miltenyi Biotec). Cells in each subpopulation were examined by smear staining using Diff-Quik solution.
Histochemistry. For staining to assess b-galactosidase activity, freshly isolated lung tissue was embedded in Tissue-Tec optimum cutting temperature compound (Sakura Finetechnicals), was frozen at À80 1C and was cut into sections 14 mm in thickness using a cryostat. The sections were fixed for 30 min at 4 1C with 2% paraformaldehyde in PBS, were washed with PBS and were incubated for 48 h at 30 1C with a solution containing 5-bromo-4-chloro-3-indolyl-b-Dgalactopyranoside (X-gal; 1 mg/ml), 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 2 mM MgCl 2 , 0.01% SDS and 0.02% Nonidet P-40. For immunohistochemistry, the lungs were first fixed by systemic perfusion with 4% paraformaldehyde in PBS and then were dissected. The dissected tissue was fixed further for 4 h and then was incubated overnight at 4 1C with 15% sucrose. Sections with a thickness of 14 mm were then prepared and, after inhibition of endogenous peroxidase activity with Peroxo-Block (Zymed), were incubated overnight at 4 1C with goat anti-mouse TARC (AF529; R&D Systems). Immune complexes were detected by incubation for 1 h at 25 1C with horseradish peroxidase-conjugated secondary antibodies (Zymed) followed by exposure to 3,3¢-diaminobenzidine.
Statistical analysis. Data are presented as means 7 s.e.m. and were analyzed by the unpaired t-test, Mann-Whitney test, or one-way or two-way analysis of variance followed by Dunnett's test with the use of Prism 3.0 and SPSS 10.1 software. A P value of less than 0.05 was considered statistically significant.
GEO accession number. Microarray data, GSE2276.
Note: Supplementary information is available on the Nature Immunology website.
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